Solid Biosciences price target lowered to $17 from $20 at Piper Sandler

Piper Sandler lowered the firm’s price target on Solid Biosciences (SLDB) to $17 from $20 and keeps an Overweight rating on the shares following quarterly results and update. Dosing is ongoing in the Phase 1/2 INSPIRE DUCHENNE trial, with next data update in about 10-12 patients expected in Q4 2025 after planned FDA meeting to discuss the accelerated approval pathway. In parallel, Solid Biosciences is gearing up for the initiation of its first-in-human Phase 1b Friedreich’s Ataxia study with SGT-212 in Q4 2025, which will include both ambulatory and non-ambulatory patients, Piper adds.